28.6 C
Vientiane
Tuesday, July 1, 2025
spot_img
Home Blog Page 157

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM

TOKYO, May 23, 2025 /PRNewswire/ — PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., Ltd. (“Eisai”), and Lenvatinib mesylate (“lenvatinib”) (*2) will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. The abstract of the study has been released today.

To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797(*3)), expansion cohort of advanced endometrial cancer patients progressed following platinum-based chemotherapy and anti-PD-(L)1 immunotherapy have been implemented by Eisai and the enrollment of 30 patients was completed. By data cutoff (Oct 22, 2024), with 9 patients remaining on treatment, 30% (9 patients) showed the confirmed response (decrease of tumor size > 30%) for an overall response rate of 30.0%. Furthermore, among patients without prior Lenvatinib treatment, the overall response rate was 42.9%.

Completing the enrollment of dose expansion cohort (n=30), the results confirmed promising preliminary antitumor activity of E7386 + Lenvatinib with a manageable safety profile. For the subsequent dose-optimization part for E7386 + LEN in advanced endometrial cancer, enrollment of patients had been initiated (NCT04008797).

(*1) E7386

E7386 is an orally available small molecule CBP/ β-catenin inhibitor that inhibits protein-protein interactions between the transcription factor CBP and β-catenin, and regulates the Wnt signaling. E7386 achieved clinical POC (Proof of concept) in October 2021 and following clinical studies are ongoing including phase I for solid tumors as monotherapy, Phase Ib for solid tumors in combination with tyrosine kinase inhibitor Lenvatinib, Phase Ib/II for solid tumors in combination with pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA.

(*2) Lenvatinib

Lenvatinib is a multi-kinase inhibitor, discovered by Eisai and being co-developed and co-commercialized under a collaboration agreement with Merck & Co., Inc., Rahway, NJ, USA, which inhibits vascular endothelial growth factor receptors (VEGFRs),VEGFR1, VEGR2, VEGFR3 and fibroblast growth factor receptors (FGFRs), FGFR1, FGFR2, FGFR3, FGFR4, and other receptor tyrosine kinases, PDGFR-alpha, KIT, RET. Lenvatinib have been approved for thyroid cancer, hepatocellular carcinoma, thymic caner and renal cell carcinoma (in combination with Everolimus or pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA.). Lenvatinib is also approved for endometrium cancer in combination with pembrolizumab 

(*3) NCT04008797

NCT04008797 is an open-label Phase Ib study of E7386 in combination with other anticancer drug, Lenvatinib for the patients with solid tumors. The study has been implemented by Eisai in Japan, Korea, Taiwan region, US, and France determine the safety and the recommended phase 2 dose (RP2D) and also to see the pharmacokinetics and efficacy of E7386 + Lenvatinib. Enrolment of each cohort of hepatic, colon, endometrial cancers are ongoing. 

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

Korean Megahit Shampoo, Grabity, Launches in Taiwan “Just wash your hair—and it’ll look thicker.”

  • The K-beauty shampoo developed by a world-renowned scientist from MIT has become a hot topic following its launch on Taiwan’s Momo Home Shopping channel

  • Clinically proven: one use increases hair thickness by 19.22% and volume by 87.27%

  • 100% vegan formula, Dermatest “Excellent” rating, eco-friendly packaging—epitomizing clean beauty

TAIPEI and SEOUL, South Korea, May 23, 2025 /PRNewswire/ — The Korean hair loss care brand Grabity, co-developed by world-renowned MIT scientist Professor Haeshin Lee and researchers from KAIST (Korea Advanced Institute of Science and Technology), officially launched in Taiwan on May 22 through Momo TV Shopping, where it received an explosive response—selling out mostly during its debut broadcast.

Korean Megahit Shampoo, Grabity, Launches in Taiwan “Just wash your hair—and it’ll look thicker.”
Korean Megahit Shampoo, Grabity, Launches in Taiwan “Just wash your hair—and it’ll look thicker.”

The live show aired at 8 PM on the 22nd, hosted by Sharon Tsui, a prominent Momo TV Shopping personality. Tsui emphasized the product’s scientific backing throughout the segment. The entire stock exhausted shortly in record time, and both Momo’s website and customer service center were soon overwhelmed with restock inquiries.

Grabity Shampoo features a high concentration of KAIST’s patented active ingredient, LiftMax 308™, a polyphenol-based complex that forms a protective barrier on hair strands to reduce damage. Clinical trials have proven that a single use increases hair thickness by 19.22% and volume by 87.27%.

Its delivery and sustained-release mechanisms were published in the peer-reviewed international journal Advanced Materials Interfaces, offering strong scientific validation.

Grabity is formulated with a 100% vegan blend using EWG Grade 1 ingredients and has earned an Excellent rating from Germany’s Dermatest, fully aligning with the rising global demand for clean beauty. The shampoo is also packaged in sustainable containers made from recycled coconut shells.

Since its launch in Korea just one year ago, Grabity has become a runaway hit—recording over 1.2 million units sold and KRW20 billion (approx. USD15M) in cumulative sales. It famously sold out in just 39 minutes at Korea’s top H&B store Olive Young, with resale prices reaching up to five times retail. Its rapid sellout in Taiwan is seen as a strong signal for further expansion across Asia’s premium beauty market.

A Momo TV Shopping spokesperson stated, “Grabity is the perfect global partner, offering functionality, a compelling brand story, and a commitment to sustainability. We look forward to bringing more world-class brands to Taiwanese consumers.”

About Polyphenol Factory
Polyphenol Factory was founded in 2023 as a startup by faculty members of KAIST (Korea Advanced Institute of Science and Technology). With a team of world-class scientists and young innovators, the company is commercializing cutting-edge technologies derived from natural polyphenols. With the vision of “innovating everyday life through science,” Polyphenol Factory is driving new waves of change in the global market.

Press Contact:
Anna Lee
yimijin@gmail.com

CARsgen’s Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 23, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced gastric/gastroesophageal junction cancer (G/GEJC) in China (CT041-ST-01, NCT04581473) is available on the American Society of Clinical Oncology (“ASCO”) website.

Title

Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician’s choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)

Abstract Number

4003

Session Type and Title

Oral Abstract Session – Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary

Session Date and Time

May 31, 2025, 3:00–6:00 PM CDT

This open-label, multicenter, randomized controlled trial (RCT) was conducted in China to compare the efficacy and safety of satri-cel versus standard of care (SOC) in CLDN18.2 positive, advanced G/GEJC patients with failure to at least 2 prior lines of treatment. The primary endpoint was PFS assessed by the Independent Review Committee (IRC). Key secondary endpoint was OS. Data cutoff date was Oct 18, 2024.

Patients were randomized (2:1) to satri-cel arm or TPC arm. For satri-cel arm, satri-cel dose of 250×106 cells were infused up to 3 times. For TPC arm, one of the standard of care (SOC) drugs (apatinib, paclitaxel, docetaxel, irinotecan or nivolumab) was given per physician’s decision. Those who experienced disease progression or drug intolerance in TPC arm could receive subsequent satri-cel, if eligible.

From Mar 29, 2022 to Aug 16, 2024, a total of 156 patients were randomized to satri-cel arm (n = 104) or TPC arm (n = 52). Twenty patients in TPC arm received subsequent satri-cel. Median number of prior systemic therapies was 2 in both arms, and 26.9% vs 19.2% had received ≥3 lines. 71.2% vs 65.4% were Lauren diffuse/mixed type. 69.2% vs 59.6% had peritoneal metastasis.

In ITT population (i.e., all randomized patients), satri-cel arm showed significant improvement in mPFS by IRC (3.25m vs 1.77m; HR 0.366, 95% CI:0.241, 0.557; p < 0.0001) meeting the primary endpoint with a 63% reduction in risk of disease progression or death. Even with 15.4% (n=16) patients in satri-cel arm failing to receive infusion and nearly 40% (n=20) patients in TPC arm receiving subsequent satri-cel, satri-cel arm still demonstrated a clear trend toward OS benefit (mOS 7.92m vs 5.49m; HR 0.693, 95% CI: 0.457, 1.051; one-sided p = 0.0416) , showing over 30% reduction in mortality risk.

More importantly, in mITT population (i.e. patients who were actually treated), 136 patients received study drug (satri-cel 88 patients vs TPC 48 patients), mPFS by IRC was 4.37m vs 1.84m, HR 0.304 (95% CI: 0.195, 0.474), representing a 70% reduction in risk of disease progression or death. The mOS was 8.61m vs 5.49m, HR 0.601 (95%CI: 0.385, 0.939), corresponding to 40% reduction in mortality risk. These results demonstrate that satri-cel treatment benefits were pronounced in patients who actually received CAR-T infusion.

Of particular note, 20 TPC patients with subsequent satri-cel infusion achieved an mOS of 9.20 months. When analyzing all 108 patients who received satri-cel infusion (88 patients in satri-cel arm and 20 patients in TPC arm), the mOS reached 9.17 months, while the mOS of 28 patients in TPC arm who did not receive satri-cel treatment was only 3.98 months (HR 0.288; 95% CI: 0.169-0.492). These findings provide further evidence that satri-cel infusion can deliver substantial survival benefits for patients.

Furthermore, satri-cel demonstrated a favorable overall safety profile. Only 4 cases of Grade 3 cytokine release syndrome (CRS) were reported, and no Grade 4-5 CRS events were observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported.

This is the first confirmatory RCT of CAR-T therapy in solid tumors. Satri-cel demonstrated significant PFS improvement and a clinically meaningful OS benefit with a manageable safety profile in CLDN18.2 positive G/GEJC patients with failure to at least 2 prior lines of treatment, compared to standard therapy. These results support satri-cel as a potential new SOC for advanced G/GEJC.

About Satri-cel

Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2 positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase I clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation of China’s National Medical Products Administration for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Binggrae to Expand Presence in Southeast Asia Through Participation in ‘THAIFEX 2025’

SEOUL, South Korea, May 23, 2025 /PRNewswire/ — Binggrae, South Korea’s leading food company, has announced its participation in ‘THAIFEX – Anuga Asia 2025,’ as part of its broader strategy to expand into Southeast Asian markets.

A bird's eye view of the booth of Binggrae 'THAIFEX 2025'
A bird’s eye view of the booth of Binggrae ‘THAIFEX 2025’

Binggrae is renowned for its diverse product lineup, including the best-selling Banana Flavored Milk and the iconic Melona ice bar. Since its founding in 1967, Binggrae has become a household name in Korea.

Binggrae will operate a promotional booth (1-KK29) at the exhibition, which will take place from May 27 to 31 in Bangkok, Thailand. Visitors will have the opportunity to explore Binggrae’s flagship products — such as Melona, Banana Flavored Milk, and Samanco (fish-shaped ice cream) — which are already available in Thailand and other Southeast Asian markets. Binggrae also aims to forge new global business partnerships during the event. Additionally, the company will showcase new product launches, as well as popular ice cream products from its subsidiary, Haitai Ice, positioning the event as a springboard for future sales growth across the region.

THAIFEX – Anuga Asia is Southeast Asia’s largest food and beverage trade show, co-hosted by Koelnmesse — the global exhibition organizer behind ANUGA, the world’s largest food trade fair held in Germany — and the Thai government. Alongside SEOUL FOOD and FOODEX Japan, it is considered one of the top three food industry exhibitions in Asia, drawing participation from over 3,100 companies representing 52 countries.

Binggrae has been exporting its ice cream products including Melona and Samanco to Thailand since 2007. These items are currently sold at premium supermarket chains such as Gourmet Market, Foodland, and Max Valu. The company has also installed branded freezers in these retail locations to enhance visibility and engagement with Thai consumers.

Looking ahead, Binggrae plans to accelerate its expansion in Southeast Asia by securing broader distribution across Thailand. The company intends to strengthen brand recognition for its ice cream portfolio through targeted marketing campaigns, with Melona at the forefront. Furthermore, Binggrae will introduce new export-exclusive Banana Flavored Milk products designed for ambient distribution, further diversifying its offerings in the region.

Meanwhile Binggrae recently launched an official global YouTube channel, O My Guide (www.youtube.com/@OMG_omyguide), which features engaging K-food content tailored to international audiences.

A Binggrae spokesperson commented, “Our participation in THAIFEX 2025 is a key step toward raising awareness of our core products among Thai consumers and accelerating our entry into the high-potential Southeast Asian market.”

Manulife Shares Responsible AI Principles at Reuters Momentum AI Summit

Jodie Wallis, Global Chief Analytics Officer, Outlines How Manulife is Using AI Responsibly

C$ unless otherwise stated                                             TSX/NYSE/PSE: MFC     SEHK: 945

TORONTO, May 23, 2025 /PRNewswire/ — Manulife’s Responsible AI Principles were shared during the Reuters Momentum AI Summit in New York last month. These principles guide the design, development, and deployment of Manulife’s Artificial Intelligence (AI) solutions, which includes over 43 GenAI use cases in production, as of Q1 2025, an equivalent amount slated to be deployed across the organization by year end and over 450 ideas in evaluation1.

Manulife’s Responsible AI Principles empower the firm to deliver value from AI for its customers, colleagues and society. With the fast pace of change in AI, Manulife will evolve its Principles as it learns and grows, as the industry matures, and as new or updated regulations emerge. Manulife’s Responsible AI Principles are:

  • To use data and AI in ways that are aligned to the company’s Code of Business Conduct and Ethics and Impact Agenda.
  • To prioritize the safety of customers, colleagues and organization through sound delivery and governance processes.
  • To endeavor to align AI efforts with a commitment to a sustainable future, by designing energy-efficient AI solutions and partnering with companies who share Manulife’s values.
  • To implement practices intended to make AI solutions and their use of data free from bias, explainable, and reliable, while maintaining the appropriate accountability for decision making.
  • To prioritize human agency and empower our colleagues to use AI tools to enhance their skills and experience, knowing these are crucial for the future.
  • To continually learn from and work with industry partners and AI experts to foster innovation and evolve our commitment to Responsible AI.

“As organizations increasingly rely on AI, being committed to responsible AI use is paramount and Manulife is proud to be a responsible AI steward,” says Karen Leggett, Global Chief Marketing Officer for Manulife. “GenAI is enabling us to better serve our customers, find innovative ways of working, and accelerate our ambition of becoming the most digital customer-centric company in our industry. At the same time, Manulife is taking great care to embed ethical AI principles in every application and workflow.”

______________________________

1 Manulife’s AI team has 450 employee-submitted ideas in queue for review.

Manulife is leading by example as Jodie Wallis, Global Chief Analytics Officer for Manulife, spoke at Reuters Momentum AI Summit in New York, where she, alongside industry leaders, discussed the future of artificial intelligence and its impact on global business. In her remarks, Wallis outlined how Manulife is using AI ethically and responsibly, providing benefits to customers while safeguarding their data and privacy.

“We are committed to harnessing AI responsibly, ensuring it aligns to our core values and supports our mission to make decisions easier and lives better,” says Wallis. “Our AI Principles highlight the importance of ethical adoption, and we are dedicated to cultivating a collaborative environment that tackles the complexities of AI while ensuring it remains safe, trustworthy, and beneficial for all.”

Manulife has been actively investing in and scaling AI capabilities since 2016. In the past three years, the firm has significantly increased the valuei enabled through advanced analytics and AI by expanding its AI solutions portfolio and increasing efficiency through data and AI platform investmentsii, all driven by the company’s responsible AI framework.

As of Q1 2025, Manulife has:

  • Over 43 GenAI use cases in production and over 450 ideas in evaluation
  • Approximately 200 data scientists and machine learning engineers
  • Global access to GenAI tools for all colleagues
  • A GenAI skills-building program for users, leaders and practitioners

The summit also provided a platform for Wallis to discuss the importance of educating and training colleagues on AI technologies.

“Empowering our workforce with the knowledge and skills to harness AI responsibly is crucial to our success and aligns with our commitment to a productive and ethical use of technology,” says Wallis.

Manulife expects its digital investments and capabilities, including AI-enabled enhancements, to generate a threefold return on investment over five years through 2027, with over $600 million of benefits2 realized in 2024 from our digital customer leadership initiatives globally. To learn more about Manulife’s AI progress, visit: manulife.com/AI

_____________________________________

2 The benefits from our global digital, customer leadership initiatives include expense saves, growth absorption, revenue benefits (margin businesses) and new business CSM growth (insurance). 

Caution regarding forward-looking statements

This document contains forward-looking statements within the meaning of the “safe harbour” provisions of Canadian provincial securities laws and the U.S. Private Securities Litigation Reform Act of 1995 with respect to Manulife’s use of its digital capabilities, including AI and AI-enabled tools, and the expected benefits it expects to realize. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to general business and economic conditions; changes in laws and regulations with respect to the use of AI-enabled tools; our ability to execute our digital plans and to deploy future digital use cases; our ability to adapt products and services to the changing market; our ability to attract and retain key employees; and our ability to protect our intellectual property and exposure to claims of infringement from others. Additional information about material risk factors that could cause actual results to differ materially from expectations may be found in our most recent annual and interim reports and elsewhere in our filings with Canadian and U.S. securities regulators.

The forward-looking statements in this document are, unless otherwise indicated, stated as of the date hereof. We do not undertake to update any forward-looking statements, except as required by law.

About Manulife  

Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong. 
 
Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com

Media Contact
Gina Simonis
617-840-4794
GSimonis@Manulife.com

Nota AI seeks KOSDAQ listing as the first AI optimization tech startup

  • Strategic partnerships with NVIDIA, Qualcomm, Samsung Electronics accelerate global expansion
  • Revenue grows tenfold in five years, validating tech-driven business model

SEOUL, South Korea, May 23, 2025 /PRNewswire/ — Nota AI, a pioneer in on-device AI, announced today the submission of its preliminary IPO application to the Korea Exchange, positioning itself as the first AI optimization technology firm to seek a KOSDAQ listing. Mirae Asset Securities serves as the lead underwriter for the IPO, which will offer approximately 2,916,000 shares publicly out of a total issuance of 21,161,880 shares.

Nota AI seeks KOSDAQ listing as the first AI optimization tech startup
Nota AI seeks KOSDAQ listing as the first AI optimization tech startup

In December last year, Nota AI became the first AI optimization technology startup to achieve an ‘A’ rating from both NICE Information Service and Korea Technology Finance Corporation, officially recognizing its technological strength and business viability.

Nota AI’s proprietary platform, NetsPresso®, automates AI model optimization, enabling efficient deployment on resource-constrained edge devices, significantly reducing operational costs. The company collaborates with global semiconductor leaders such as NVIDIA, Qualcomm, Samsung Electronics, Arm, and Sony, driving continuous technological innovation and market expansion. Nota AI’s notable client base includes several Fortune Global 500 companies. Recently, CB Insights recognized Nota AI as one of the “100 Most Innovative AI Startups,” underscoring its global recognition.

Nota AI’s generative AI-based video monitoring solution, Nota Vision Agent (NVA), has successfully been deployed in diverse sectors such as industrial safety, transportation, and retail. Recently, Nota AI secured a landmark agreement with Dubai’s Roads and Transport Authority, the first-ever Korean firm to do so, demonstrating its strong international commercial viability.

Proceeds from the IPO will support the recruitment of top-tier talent, enhance global market expansion efforts, and accelerate the advancement of its product offerings. Nota AI currently operates international subsidiaries in Berlin, Germany (since 2020), and Sunnyvale, USA (since 2022), and is actively expanding into key markets including the Middle East, Japan, and Southeast Asia.

“Our IPO filing is a critical milestone affirming our position as global leaders in AI optimization technology,” said Myungsu Chae, CEO of Nota AI. “This IPO will accelerate our innovation capabilities and significantly boost our global market penetration.”

Since its inception, Nota AI has secured $42.6 million in investments from prominent investors including Samsung, LG, Naver D2SF, and Kakao. Last year, the company’s revenue reached $5.86 million, representing a substantial 136% growth year-over-year, with continued strong growth projected to exceed 67% this year, reflecting the robust scalability of its technology-driven business model.

Webull Reports First Quarter 2025 Financial Results

Total revenues grew 32% year-over-year to $117 million, reflecting strong account and trading volume growth

Customer assets increased 45% year-over-year, driven by increased customer net deposits

Disciplined execution alongside robust revenue growth driving profitability

ST. PETERSBURG, Fla., May 23, 2025 /PRNewswire/ — Webull Corporation (NASDAQ: BULL) (“Webull” or the “Company”) today announced financial results for the quarter ending March 31, 2025.

“We are proud to have delivered a very strong first quarter, driven by significant account and trading volume growth that reflects continued demand for Webull’s differentiated trading platform,” said Anthony Denier, Webull’s Group President and U.S. CEO. “We believe our results speak to our strong value proposition, reliable and innovative platform, and focus on global distribution to meet the needs of our sophisticated retail customers. Moving forward we will remain focused on broadening our product portfolio, introducing new asset classes, and expanding access to customers globally, all with the goal of strengthening the customer experience to further expand our position as the advanced retail investment platform of choice.”

“In the first quarter, we continued to execute on our strategy and achieved impressive momentum across the business, growing total revenues by 32% alongside strong improvements on the bottom line,” said H.C. Wang, Group CFO of Webull. “We continue to see strong account growth as our global teams execute on our strategy in 2025 to address and meet the long-term investing needs of individual investors around the world.”

First Quarter Business and Financial Highlights                                                                                 

  • Total revenues increased 32% year-over-year to $117.4 million.
  • Trading-related revenue increased 52% year-over-year.
  • Total operating expenses decreased 2.0% year-over-year to $96.8 million.
  • Adjusted operating expenses increased 2.4% year-over-year to $88.7 million.
  • Income before income taxes increased $29.3 million year-over-year from a loss of $9.8 million to income of $19.5 million.
  • Net income attributable to the Company increased $25.5 million year-over-year from a loss of $12.6 million to income of $12.9 million.
  • Adjusted operating profit totaled $28.7 million for the quarter, representing an increase of $26.4 million year-over-year and a 22 percentage point improvement in operating margin to 24.4%.
  • Customer assets totaled $12.6 billion, representing 45% year-over-year growth, driven by strong net deposits, which grew 66% year-over-year.
  • Registered users increased 17% year-over-year to 24.1 million users.
  • Funded accounts increased to 4.7 million, representing 10% year-over-year growth.
  • Equities notional volume grew to $128 billion, a 15% year-over-year increase.
  • Options contracts volume grew to 121 million, an 8% year-over-year increase.
  • DARTs increased to 924 thousand, representing a 44% year-over-year growth.

Company Highlights

  • In February, we partnered with Kalshi, the first CFTC-regulated exchange with prediction markets, to offer our users the ability to trade binary event contracts on the Webull platform. Webull initially offered S&P 500 and Nasdaq hourly binary contracts.
  • In March, we successfully launched Webull Premium, a subscription-based membership service that unifies the Company’s best-in-class products and offers an elevated investing experience for our users. As of May 15, 2025, Webull Premium had approximately 40,000 users, representing nearly $2.0 billion in customer assets.
  • Subsequent to the close of the first quarter, Webull consummated its previously announced business combination and its Class A ordinary shares, warrants and incentive warrants began trading on Nasdaq.
  • In May, we enhanced the Webull Advisors platform by partnering with BlackRock to offer model portfolios. Webull Advisors now delivers intelligent, automated wealth management tools to its U.S.-based customers. Investors can now access a range of professionally managed, diversified portfolios across various asset classes, including alternatives and digital assets.
  • In May, we also announced our collaboration with Visa on the U.S. platform, whereby Webull users can efficiently transfer money between their Webull brokerage account and external bank accounts through Visa Direct.

Conference Call Information

Webull will host a conference call to discuss its results at 5:00 p.m. E.T. today, May 22, 2025. The conference call can be accessed at https://event.choruscall.com/mediaframe/webcast.html?webcastid=SMs1hkAY or participants may dial 1-866-652-5200 (U.S.) or 1-412-317-6060 (international).

Following the call, a replay and transcript will be available on the Company’s website at www.webullcorp.com/investor-relations, as well as the earnings press release and accompanying slide presentation.

About Webull Corporation 

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, and fractional shares through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

Contacts

For Investors
ir@webullcorp.com 

For Media
5W Public Relations
Nicholas Koulermos
Webull@5wpr.com
(212) 999-5585

Use of Non-GAAP Financial Measures

We use adjusted operating profit and adjusted operating expenses, both non-GAAP financial measures, to evaluate our operating results and for financial and operational decision-making purposes.  Adjusted operating profit represents income (loss) from continuing operations, before income taxes, excluding share-based compensation expenses, and other expense (income), net.  Adjusted operating expenses represent total operating expenses, excluding share-based compensation expenses.

We believe that both adjusted operating profit and adjusted operating expenses help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in income from continuing operations, before income taxes, and total operating expenses. We believe that adjusted operating profit and adjusted operating expenses provide useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

Adjusted operating profit and adjusted operating expenses should not be considered in isolation or construed as an alternative to income from continuing operations, before income taxes, and total operating expenses or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to compare the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted operating profit and adjusted operating expenses presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

For more information on these non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of Non-GAAP and GAAP Financial Measures” set forth at the end of this press release.

Definitions

“Customer assets” refer to the sum of the fair value of all equities, ETFs, options, warrants, futures, and cash held by customers in their Webull brokerage accounts, net of customer margin balances, as of the record date. While customer assets are significantly impacted by mark-to-market valuations of customers’ investments, we consider customer assets an important metric as growth in customer assets generally leads to an increase in trading volumes and revenue.

“DARTs” refers to daily average revenue trades, which is the number of customer trades executed during a given period divided by the number of trading days in that period. DARTs provide us information on how active our customers trade. A limitation of this metric is that it does not capture the size of the trade and revenue per trade varies significantly depending on size and type of trades.

“Equities notional volume” refers to the aggregate dollar value (purchase price or sale price as applicable) of trades executed over a specified period of time. Equity notional volume directly drives our equities trading revenue, as we earn payment for order flow or commissions for customers’ equities trades based on a percentage of notional value. However, equity notional volume is highly sensitive to market conditions in the short-term, which makes predicting our equity trading revenue with precision difficult.

“Funded accounts” refer to Webull brokerage accounts into which the customer has made an initial deposit or money transfer, of any amount, whose account balance (which is measured as the fair value of assets in the customer’s account less the amount due from the customer) has not dropped to or below zero for 45 consecutive calendar days as of the record date. Funded accounts reflect unique customers, and multiple funded accounts by a single customer are counted as one funded account. Growth in our funded accounts provides insight as to the effectiveness of our marketing efforts and our ability to acquire monetizable customers. Funded accounts are positively correlated with, but are not determinative, of customer assets, trading volumes, and revenue.

“Options contracts volume” refers to the total number of options contracts bought or sold over a specified period of time. Options contracts volume directly drives our options trading revenue, as we earn payment for order flow or commissions for customers’ options trades on a per contract basis. However, options contracts volume is highly sensitive to market conditions in the short-term, which makes predicting our options trading revenue with precision difficult.

“Registered users” refer to those users who have registered on our platform but not necessarily have opened a brokerage account with one of our licensed broker-dealers. Growth in our registered users provides insight as to the popularity of the Webull App. While we do not generate revenue from registered users who do not have brokerage accounts with us, registering an account on the Webull App is the first step toward opening and funding a brokerage account with us. 

Webull Corporation

Condensed Consolidated Statements of Financial Position

March 31,
2025

December 31,
2024

(Unaudited)

Assets

Cash and cash equivalents

$

297,480,490

$

270,728,008

Cash and cash equivalents segregated under federal and foreign requirements

906,742,825

939,232,153

Receivables from brokers, dealers, and clearing organizations

219,258,173

262,093,040

Receivables from customers, net

299,765,984

301,107,428

Prepaid expenses and other current assets

61,313,557

50,344,836

Customer-held fractional shares

105,839,019

108,252,531

Total current assets

1,890,400,048

1,931,757,996

Right-of-use assets

64,604,135

66,293,751

Property and equipment, net

33,204,229

33,629,770

Intangible assets, net

19,937,282

19,415,963

Goodwill

5,197,438

5,197,438

Deferred tax assets

10,159,867

12,374,499

Total non-current assets

133,102,951

136,911,421

Total assets

$

2,023,502,999

$

2,068,669,417

Liabilities, mezzanine equity, and shareholders’ equity

Payables due to customers

$

1,312,281,169

$

1,378,625,130

Payables due to brokers, dealers, and clearing organizations

5,684,067

1,490,537

Lease liabilities – current portion

3,384,966

4,969,959

Accounts payable and other accrued expenses

56,827,363

61,079,799

Total current liabilities

1,378,177,565

1,446,165,425

Lease liabilities – non-current portion

10,318,113

10,438,555

Deferred tax liabilities

5,484,358

5,292,255

Total non-current liabilities

15,802,471

15,730,810

Total liabilities

1,393,980,036

1,461,896,235

Commitments and Contingencies

Mezzanine equity

Convertible redeemable preferred shares (aggregate liquidation preference of
$644,274,805 and $644,132,365 as of March 31, 2025 and December 31, 2024,
respectively; and aggregate redemption value of $2,883,451,470 and
$2,861,748,733 as of March 31, 2025 and December 31, 2024, respectively)

2,883,451,470

2,861,748,733

Total mezzanine equity

2,883,451,470

2,861,748,733

Shareholders’ deficit

Class A ordinary shares ($0.0001 par value; 4,000,000,000 shares authorized,
143,531,581 and 139,307,244 shares issued and outstanding, respectively, as of
March 31, 2025 and December 31, 2024) 

13,931

13,931

Class B ordinary shares ($0.0001 par value, 1,000,000,000 shares authorized,
no shares issued and outstanding as of March 31, 2025 and December 31, 2024,
respectively;)

Treasury shares (4,224,356 shares as of March 31, 2025 and December 31, 2024)

Additional paid in capital

Accumulated deficit

(2,241,614,509)

(2,241,066,624)

Accumulated other comprehensive loss

(13,426,170)

(15,195,946)

Total shareholders’ deficit

(2,255,026,748)

(2,256,248,639)

Noncontrolling interest

1,098,241

1,273,088

Total deficit

(2,253,928,507)

(2,254,975,551)

Total liabilities, mezzanine equity, and total deficit

$

2,023,502,999

$

2,068,669,417

 

Webull Corporation

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

For the Three Months Ended
March 31,

2025

2024

Revenues

Equity and option order flow rebates

$

64,111,182

$

43,912,117

Interest related income

31,140,064

32,497,629

Handling charge income

17,547,010

9,704,509

Other revenues

4,570,579

2,821,465

Total revenues

117,368,835

88,935,720

Operating expenses

Brokerage and transaction

23,245,456

17,932,844

Technology and development

16,924,892

14,890,082

Marketing and branding

22,991,038

34,014,065

General and administrative

33,620,720

31,908,841

Total operating expenses

96,782,106

98,745,832

Other expense, net

1,089,417

26,492

Income (loss) before income taxes

19,497,312

(9,836,604)

Provision for income taxes

6,558,225

2,715,461

Net income (loss)

12,939,087

(12,552,065)

Less net loss attributable to noncontrolling interest

(146,720)

(121,820)

Net income (loss) attributable to the Company

13,085,807

(12,430,245)

Preferred shares redemption value accretion

(21,702,737)

(1,087,707,813)

Net loss attributable to ordinary shareholders

$

(8,616,930)

$

(1,100,138,058)

Net loss per share attributable to ordinary shareholders

Basic and diluted

$

(0.06)

$

(7.98)

Weighted-average shares outstanding

Basic and diluted

139,307,224

137,814,433

Net income (loss)

$

12,939,087

$

(12,552,065)

Other comprehensive loss, net of tax:

Change in cumulative foreign currency translation adjustment

1,741,649

(2,772,734)

Other comprehensive income (loss)

1,741,649

(2,772,734)

Comprehensive income (loss)

14,680,736

(15,324,799)

Less comprehensive loss attributable to noncontrolling interest

(146,720)

(121,820)

Less foreign currency translation adjustment attributable to noncontrolling interest        

(28,127)

(10,435)

Preferred shares redemption value accretion

(21,702,737)

(1,087,707,813)

Comprehensive loss attributable to ordinary shareholders

$

(6,847,154)

$

(1,102,900,357)

 

Webull Corporation

Unaudited Reconciliation of Non-GAAP and GAAP Financial Measures

Adjusted Operating Expenses Reconciliation

(Unaudited)

For the Three Months Ended
March 31,

2025

2024

Total operating expenses (GAAP)

$            96,782,106

$            98,745,832

Less:  Share-based compensation

8,069,045

12,136,815

Adjusted operating expenses (Non-GAAP)

$            88,713,061

$            86,609,017

Adjusted Operating Profit Reconciliation

(Unaudited)

For the Three Months Ended
March 31,

2025

2024

Income (loss) before income taxes (GAAP)

$            19,497,312

$            (9,836,604)

Add: Other expense (income), net

1,089,417

26,492

Add: Share-based compensation

8,069,045

12,136,815

Adjusted operating profit (Non-GAAP)

$            28,655,774

$              2,326,703

Contra Revenue Impact

Most of our platform users are not considered customers under ASC 606, Revenues from Contracts with Customers (“ASC 606”), and promotional payments made to these platform users are accounted for as a marketing and branding expense. Conversely, for our platform users who have been determined to be customers under ASC 606, we account for these promotional payments as a reduction in revenue.  The following presents how contra revenue impacted our trade related revenues.

For the Three Months Ended
March 31,

2025

2024

(unaudited) 

(unaudited)

Contra revenue impact on:                            

Option handling fees

$         (118,541)

$       (120,892)

Platform and trading fees

(2,709,988)

(956,392)

Total contra revenue

$      (2,828,529)

$     (1,077,284)

Statement regarding unaudited financial and operational information

The unaudited financial and operational information included in this press release is subject to potential adjustments and is based on the information available to management at this time. Potential adjustments to operational and consolidated financial information may be identified from work performed during Webull’s preparation of financial statements subsequently hereto or its year-end audit. Information may also be presented differently from the information included herein in the future. This could result in significant differences from the unaudited or other historical operational and financial information included herein. The financial information included in this press release does not reflect the closing of the previously announced business combination that occurred on April 10, 2025.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release or other statements of the Company, including, for instance, statements as to business strategy and plans, future results of operations and financial position, planned products and services, objectives of management for future operations or strategies of the Company, market size and growth opportunities, competitive position and technological and market trends are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “anticipate,” “expect,” “suggests,” “plan,” “believe,” “predict,” “potential,” “seek,” “future,” “propose,” “continue,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology.

All forward-looking statements are based upon current estimates and forecasts and reflect the reasonable views, assumptions, expectations, and opinions of the Company and its management as of the date of this press release, and are therefore subject to a number of factors, risks and uncertainties, some of which are not currently known to the Company and its management and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to: (1) the ability of the Company to capitalize on the anticipated benefits of the business combination, to grow and manage growth profitably, maintain relationships and deepen engagement with users, customers and suppliers, and retain its management and key employees; (2) the reliance of key functions of the Company’s business on third-parties and the risk that the Company’s platform and systems rely on software and applications that are highly technical and may contain undetected errors that could result in unexpected network interruptions, failures, security breaches, or computer virus attacks; (3) the risks associated with the Company’s global operations and continued global expansion, including, but not limited to, the risks related to complex or constantly evolving political or regulatory environments that may result in substantial costs or require adverse changes to the Company’s business practices; (4) the Company’s estimates of expenses and costs (including costs related to the business combination), of profitability or of other operational and financial metrics as well as the Company’s expectations regarding demand for and market acceptance of its products and service; (5) the Company’s reliance on trading related income, including payment for order flow (“PFOF”), and the risk of new regulation or bans on PFOF and similar practices; (6) the Company’s exposure to fluctuations in interest rates, rapidly changing interest rate environments, volatile prices of securities and trading volumes; (7) the Company’s reliance on a limited number of market makers and liquidity providers to generate a large portion of its revenues, and the negative impact of the loss of any of those market makers or liquidity providers; (8) the effects of competition in the Company’s industry and the Company’s need to constantly innovate and invest in new markets, products, technologies or services to retain, attract and deepen engagement with users; (9) changes in international trade policies and trade disputes that could result in tariffs, taxes or other protectionist measures adversely affecting our business; (10) risks related to general political, economic and business conditions globally and in jurisdictions where the Company operates; (11) risk of further actions taken by various government bodies in the United States that have made the Company the subject of inquiries and investigations relating to concerns about our connections to China; (12) the risk that the failure to protect customer data and privacy or to prevent security breaches relating to the Company’s platform could result in economic loss, damage to its reputation, deter customers from using its products and services, and expose it to legal penalties and liability; (13) risks related to the Company’s need as a regulated financial services company to develop and maintain effective compliance and risk management infrastructures as well as to maintain capital levels required by regulators and self-regulatory organizations; (14) the ability to meet, or continue to meet, stock exchange listing standards; (15) the possibility of adverse developments in pending or new litigation and regulatory investigations; (16) risks related to the Company’s securities and its status as a foreign private issuer and the fact that the information the Company is required to file with or furnish to the U.S. Securities and Exchange Commission (the “SEC”) may be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers; (17) risks related to the offer and resale of our securities, such as dilution from the issuance of additional Class A ordinary shares upon the exercise of warrants, and increased volatility, or significant declines, in the price of our securities based on increased trading activity and the perception that sales of our securities may occur; and (18) other risks and uncertainties that are more fully described in filings made, or to be made, by the Company with the SEC, including in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC. The foregoing list of factors is not exhaustive. There may be additional risks that the Company and its management presently do not know about or that the Company and its management currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In light of these factors, risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur, and any estimates, assumptions, expectations, forecasts, views or opinions set forth in this press release should be regarded as preliminary and for illustrative purposes only and accordingly, undue reliance should not be placed upon the forward-looking statements. The Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Reported results should not be considered an indication of future performance.

 

China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency

BEIJING, May 23, 2025 /PRNewswire/ — China Liberal Education Holdings Limited (“China Liberal” or the “Company”) (Nasdaq: CLEU), a China-based company that provides technological consulting services for smart campus solutions and other educational services, today announced that on May 21, 2025, it received an additional staff determination notice (the “Additional Staff Determination Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended December 31, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1).

China Liberal has previously submitted a request for hearing before the Nasdaq’s Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing before the Panel has been scheduled on June 10, 2025. In accordance with the timeline established previously by Panel and since the Company is already before the Panel, it will have seven days, or until May 28, 2025, to request a stay of the suspension, pending a Panel decision. The Panel will review the request for an extended stay and notify the Company of its conclusion as soon as practicable, but in any event no later than 15 calendar days following the deadline to request a further stay.

In the meantime, the Company is actively engaged with the necessary parties to finalize and file its delayed Form 20-F, which has been substantially drafted before the original filing deadline. While the timeline for completion remains uncertain, the Company is making every effort to advance the process as efficiently as possible. The Company’s operations are not affected by the receipt of the Staff Determination Notice dated May 7, 2025 and the Additional Staff Determination Notice.

This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About China Liberal Education Holdings Limited

China Liberal is an educational services provider headquartered in Beijing, China. China Liberal provides a wide range of services, including technological consulting for Chinese universities to improve their campus information and data management systems, designed to enhance the teaching, operating, and management environment of the universities, thus establishing a “smart campus.” Additionally, China Liberal offers tailored job readiness training for graduating students. For more information, please visit the Company’s website at http://ir.chinaliberal.com/.

Forward-Looking Statements

This document contains forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s expectations and projections about future events, which the Company derives from the information currently available to the Company. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those using terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. When evaluating these forward-looking statements, you should consider various factors, including our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as required by law. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can provide no assurance that these expectations will prove to be accurate, and it cautions investors that actual results may differ materially from the anticipated results. Investors are encouraged to review the risk factors that may affect future results in the Company’s filings with the SEC.

Investor Relations Contact

China Liberal Education Holdings Limited
Email: ir@chinaliberal.com 

Ascent Investor Relations LLC
Tina Xiao
President
Phone: +1-646-932-7242
Email: investors@ascent-ir.com